Back to Search
Start Over
Initial Evaluation of [F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
- Source :
- Molecular Imaging & Biology; Aug2015, Vol. 17 Issue 4, p565-574, 10p
- Publication Year :
- 2015
-
Abstract
- Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUV up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [F]DCFPyL is similar to that from other PET radiotracers. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15361632
- Volume :
- 17
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Molecular Imaging & Biology
- Publication Type :
- Academic Journal
- Accession number :
- 103669716
- Full Text :
- https://doi.org/10.1007/s11307-015-0850-8